AMN Stock Recent News

AMN Healthcare is poised for revenue growth due to new remote language interpretation systems and a shift in U.S. age demographics. The company's innovative solutions like WorkWise and ShiftWise Flex enhance efficiency, supporting robust financial performance and a higher target stock price. AMN benefits from the increasing number of insured individuals in the U.S., driving national healthcare expenditures and potential revenue growth.

In Q4 2024 AMN Healthcare posted meaningful sequential revenue growth for the first time in 2 years, suggesting its cyclical decline might be coming to an end. A variety of indicators shows stabilisation in the market, but an upward inflection doesn't seem imminent. Long-term growth and margin drivers like platformization and a larger tech segment are intact, but acquisitions are on hold due to high debt.

AMN, CABGY and BNPQY have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2025.

AMN Healthcare's dismal results in the majority of its segments led to a soft overall fourth-quarter performance.

AMN Healthcare Services, Inc. (NYSE:AMN ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Randall Reese - Senior Director of Investor Relations and Strategy Cary Grace - President and Chief Executive Officer Brian Scott - Chief Financial Officer and Chief Operating Officer Conference Call Participants Jasper Bibb - Truist Securities, Inc. A.J. Rice - UBS Investment Bank Jeffrey Silber - BMO Capital Markets Joanna Gajuk - Bank of America Merrill Lynch Mark Marcon - Robert W.

Although the revenue and EPS for AMN Healthcare (AMN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AMN Healthcare Services (AMN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $1.32 per share a year ago.

Quarterly revenue of $735 million; GAAP loss of ($4.90)/share and adjusted EPS of $0.75

Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AMN Healthcare (AMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.